Table 3.
Pooled HR and heterogeneity of the meta-analysis of OS in patients with certain types of solid tumors.
| Factor | No. of cohorts | Model | Pooled HR (95%CI) | P | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2 | P | |||||
| CD56 | ||||||
| OS for CRC | 4 | R | 0.574 (0.328, 1.004) | 0.052 | 62.9% | 0.044 |
| OS for glioma | 2 | R | 0.933 (0.050, 17.523) | 0.963 | 88.7% | 0.003 |
| OS for HCC | 2 | R | 0.620 (0.124, 3.109) | 0.561 | 79.2% | 0.028 |
| OS for HNSCC | 4 | F | 0.356 (0.237, 0.533) | <0.001* | 31.4% | 0.224 |
| CD57 | ||||||
| OS for CRC | 5 | F | 0.529 (0.376, 0.746) | <0.001* | 34.6% | 0.191 |
| OS for ESCC | 4 | F | 0.577 (0.426, 0.782) | <0.001* | 34.3% | 0.206 |
| OS for GC | 3 | F | 0.583 (0.395, 0.861) | 0.007* | 0.0% | 0.405 |
| OS for HCC | 2 | F | 0.528 (0.367, 0.760) | 0.001* | 40.8% | 0.194 |
| OS for HNSCC | 5 | R | 0.326 (0.136, 0.785) | 0.012* | 76.9% | 0.002 |
| OS for NSCLC | 2 | F | 0.301 (0.172, 0.528) | <0.001* | 0.0% | 0.383 |
| OS for RCC | 2 | R | 0.713 (0.361, 1.406) | 0.329 | 84.7% | 0.010 |
R, random-model; F, fixed-model;
*
p < 0.05.